140+
Patients With CAR T-Cell Therapy
to Date Across Commercial and
Clinical care settings
844.482.4812
asksarah@sarahcannon.com
For more information:
Learn more about us at sarahcannon.com/bloodcancernetwork
1122/19SCB29-4/R4
Immune Cell
Therapy Committees
• Coordination and Standardization
of Research Processes Across
Centers for Both Blood Cancer and
Solid Tumor Indicators
• Local Committees Comprised of
Site Transplant, Nursing, Research
Staff, and Physicians Meet Monthly
at Each Sarah Cannon Blood Cancer
Network Center
• Local Committees Report to Sarah
Cannon Immune Effector Cell
Therapy Leadership Monthly
Studies Open in:
• Multiple Myeloma
• Diffuse Large B-Cell
Lymphoma
• Mantle Cell Lymphoma
• Indolent Non-Hodgkin
Lymphoma
• B-Cell Non-Hodgkin
Lymphoma
• ALL
• CLL/SLL
• AML/MDS
• Multi Indication Solid Tumor
• Sarcoma
• Melanoma
• Non-Small Cell Lung Cancer
• CRISPR CD34+ Gene
Therapy Sickle Cell Disease
• Biomarker Driven Basket
Trial
Commercial CAR
T-Cell Therapy
• 5 Programs in U.S. Certified
by Novartis
• 5 Programs in U.S. Certified
by Kite
• 1 Program in UK in Certified
by Gilead
Immune Effector Cell
Therapy Studies Activated
Since December 2015
30+
How We're Advancing Blood Cancer Care
Through Cellular Therapy
Immune Effector Cell Therapy